We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Rosetta Genomics and Collaborators Unveil Colon Cancer Screening Diagnostic
News

Rosetta Genomics and Collaborators Unveil Colon Cancer Screening Diagnostic

Rosetta Genomics and Collaborators Unveil Colon Cancer Screening Diagnostic
News

Rosetta Genomics and Collaborators Unveil Colon Cancer Screening Diagnostic

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Rosetta Genomics and Collaborators Unveil Colon Cancer Screening Diagnostic"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Rosetta Genomics Ltd. and collaborators have unveiled initial data relating to the company's colorectal cancer screening diagnostics test, miRscreen™ colon, which is based on a simple blood draw, and is expected to be released next year.

The company's scientists and collaborators have identified microRNA biomarkers in serum, which have the potential to accurately differentiate colorectal cancer patients from healthy individuals. The data is being presented at the ASCO 2009 Gastrointestinal Cancers Symposium, in San Francisco.

"The initial data presented by Rosetta is very significant" said Aaron Ciechanover, Nobel laureate and chairman of Rosetta's scientific advisory board. "Rosetta's scientists and their collaborators, have for the first time, identified in serum, potential microRNA biomarkers of colorectal cancer. If treated early, 90% of colon cancer patients survive. The humane, medical, and financial impact of an effective, non-invasive colon cancer screening test can not be overstated."

The company, together with collaborators, has shown that two microRNA biomarkers, obtained from a simple blood draw, identified colon cancer patients from healthy individuals with 91% sensitivity and 72% specificity.
Advertisement